Literature DB >> 2895737

Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats.

J Tsoporis1, F H Leenen.   

Abstract

In spontaneously hypertensive rats (SHR), the progression (or absence of regression) of cardiac hypertrophy despite adequate blood pressure (BP) control by arterial vasodilators has been attributed to increased cardiac sympathetic activity. We evaluated changes in indices of general and cardiac sympathetic tone in relation to changes in cardiac anatomy during treatment of normotensive rats and SHR with hydralazine, 120 mg/L, or minoxidil, 120 mg/L of drinking water. In SHR, both vasodilators reduced BP rapidly and consistently. Significant increases in heart rate and plasma norepinephrine were observed only in the initial 2 days of arterial vasodilator treatment. After 5 weeks of treatment, marked increases in left and right ventricular sympathetic activity (as assessed by norepinephrine turnover rates) were present, but no increase was seen in heart rate and plasma norepinephrine. Intravascular volume expansion was observed on Day 14 of minoxidil and Day 35 of hydralazine treatment. Prolonged treatment with minoxidil induced significant increases in left ventricular internal diameter, as well as in left and right ventricular weights, but not in the wall thickness of the left ventricle. Treatment with hydralazine did not affect left ventricular weight and caused a small increase in the weight of the right ventricle. In normotensive rats, both vasodilators initially decreased BP, but tolerance developed within 1 to 2 weeks of treatment. Plasma norepinephrine and heart rate showed increases only at Day 1 of either treatment, whereas cardiac sympathetic hyperactivity persisted at 2 and 5 weeks of treatment. Changes in cardiac anatomy were qualitatively similar to those observed in SHR. We conclude that, during treatment of normotensive rats and SHR with arterial vasodilators, cardiac sympathetic hyperactivity persists and may be involved in the cardiac effects of arterial vasodilators. However, other mechanisms, such as chronic cardiac volume overload, may also play an important role, particularly with minoxidil.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2895737     DOI: 10.1161/01.hyp.11.4.376

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

Review 1.  Pulmonary Hypertension and ATP-Sensitive Potassium Channels.

Authors:  Conor McClenaghan; Kel Vin Woo; Colin G Nichols
Journal:  Hypertension       Date:  2019-05-28       Impact factor: 10.190

2.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study.

Authors:  Christian Höcht; Carla Di Verniero; Javier A W Opezzo; Guillermo F Bramuglia; Carlos A Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-30       Impact factor: 3.000

3.  Topical minoxidil: cardiac effects in bald man.

Authors:  F H Leenen; D L Smith; W P Unger
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

4.  Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability.

Authors:  Facundo Martín Bertera; Julieta Sofía Del Mauro; Diego Chiappetta; Ariel Héctor Polizio; Fabián Buontempo; Carlos Alberto Taira; Christian Höcht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-03       Impact factor: 3.000

5.  Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil.

Authors:  S Takeo; A B Elmoselhi; R Goel; E Sentex; J Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-10       Impact factor: 3.396

6.  Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A.

Authors:  Y Li; Y Saito; K Kuwahara; X Rong; I Kishimoto; M Harada; M Horiuchi; M Murray; K Nakao
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

Review 7.  Kir6.1 and SUR2B in Cantú syndrome.

Authors:  Conor McClenaghan; Colin G Nichols
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

8.  Inhibition of norepinephrine-induced cardiac hypertrophy in s100beta transgenic mice.

Authors:  J N Tsoporis; A Marks; H J Kahn; J W Butany; P P Liu; D O'Hanlon; T G Parker
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

9.  Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat.

Authors:  I Ostman-Smith
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects.

Authors:  Iñaki Robles-Vera; Marta Toral; Néstor de la Visitación; Manuel Sánchez; Manuel Gómez-Guzmán; Raquel Muñoz; Francesca Algieri; Teresa Vezza; Rosario Jiménez; Julio Gálvez; Miguel Romero; Juan Miguel Redondo; Juan Duarte
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.